~~<i id='404AC5A72C'><strike id='404AC5A72C'><tt id='404AC5A72C'><pre id='404AC5A72C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：comprehensive 2025-08-06 04:47:10 - browse：18235

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： People with substance use disorder deserve online privacy

explore

hotspot

entertainment

explore

hotspot

Medicareplanstopaymoreforatypeofcardiacrehabilitationthattakesplaceincertainoutpatientclinicsownedby

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

PBMs drew scrutiny in House hearing — and so did pharma

CZI to create biohub to build anti

Akili changes sales model for its ADHD video game treatment

Readout LOUD podcast: Live from the 2023 STAT Summit

Neurocrine congenital adrenal hyperplasia trial succeeds

explore

comprehensive

explore

Drug repurposing or repositioning? The language matters

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Peter Hotez and the public health issue of online harassment

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: The economic case for universal basic health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roivant's CEO is a star, but biotech's black hole persists

Novavax promises a turnaround & Lilly roils the obesity market

Roche acquires Telavant from Roivant, adding experimental IBD treatment

hotspot

The struggle to figure out which patients 'deserve' Wegovy

STAT Summit: Meghan O’Rourke on making chronic illness visible

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

entertainment

explore

hotspot